145.85 -0.59 (-0.40%)
Pre-Market: 5:04AM EST
|Bid||146.55 x 900|
|Ask||146.95 x 1000|
|Day's Range||146.35 - 148.75|
|52 Week Range||118.62 - 148.75|
|Beta (3Y Monthly)||0.31|
|PE Ratio (TTM)||257.38|
|Earnings Date||Jan 22, 2019|
|Forward Dividend & Yield||3.60 (2.47%)|
|1y Target Est||148.11|
NEW YORK, NY / ACCESSWIRE / November 21, 2018 / U.S. markets plunged on Tuesday as FAANG (Facebooks, Amazon, Apple, Netflix and Google) stocks entered into bear market territory, pressuring the tech sector ...
It remains the most referenced guide to prosperity because of its moral force: Smith said the freest markets are led by an invisible hand benefiting everyone, not just the individuals and companies motivated by their own profit. American free enterprise is achieving the greatest growth in the developed world, posting annual gross domestic product gains since 2009. Within just eight years of the global financial crisis, the U.S. was the only non-emerging-market economy with record GDP.
Glaxo (GSK) submits sBLA to the FDA seeking label expansion of its asthma drug, Nucala, in pediatric patients in the United States.
The Nasdaq got smacked with its biggest single-session loss in more than three weeks and nearly faced a test of the psychologically important 7000 level.
On November 16, Merck’s (MRK) stock price closed at $76.06, which represents ~1.63% growth from its close of $74.84 on November 15. Merck’s stock price grew from $56.79 when the market opened on January 2 to $76.06 when the market closed on November 16, which representing ~34% year-to-date growth. On November 16, Merck hit its 52-week high of $76.25.
The broad market is correcting deeply for a second straight trading session, with the big S&P 500 gapping down to re-test the lows set in October -- during the worst month for stocks since 2011. Tuesday shares are managing to hold up much better than the broad market.
Most stocks have been thoroughly shaken and stirred since early October, and a long-overdue corrective move finally took shape. Not even the bluest of the blue chips have been immune. The Dow Jones Industrial Average still is off its record high from a couple months ago, and several Dow stocks still are vulnerable to more selling. The initial shellshock has started to fade, however, the smoke is clearing and some stocks are recovering. Smart investors are now weighing the impact and searching for opportunities. Some Dow Jones stocks may have more downside to dish out, but a handful of these iconic names are looking oversold, undervalued and ripe for a rebound sooner than later. Remember: Corporate earnings have never been better, and consumer confidence is as high as it's been in years. Clearly something is going right. Here's a look at five Dow stocks that may have more ground to give up before they hit bottom, and two industrial-average components that may already be buys at current prices. But a note: Most of these "stocks to sell" are merely in short-term trouble. A sizable pullback from any of them could ultimately turn into a buying opportunity. SEE ALSO: 12 Vulnerable Stocks to Watch on Market-Wide Weakness
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 19) Merck & Co., Inc. (NYSE: MRK ) Down In The Dumps (Biotech ...
continues to struggle with management issues and the shortfall in Apple orders drove it to a new recent low. With those two stocks under heavy pressure there weren't any buyers rushing to buy the other big-cap technology names. Retail, biotechnology, software, semiconductors and most all of the sectors that lead in a strong market were down Monday.
The major indices continue to see extreme selling pressure. Breadth is running about 1,750 gainers to 5,350 decliners and new 12-month lows are over 300. There is a steady diet of bad news and no immediate technical support until the lows of October are retested.
"PFE's oncology assets will make up 13% of its total 2018 sales, according to FactSet, and they will accelerate PFE's sales growth for the foreseeable future, but these drugs are underappreciated," Cantor Fitzgerald analyst Louise Chen wrote on Sunday. The cancer drug market is expected to accelerate quickly in the coming years, growing from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020, according to Allied Market Research.
Johnson & Johnson's (J&J) apalutamide gets positive CHMP opinion for the treatment of adult patients with non-metastatic castration-resistant prostate cancer.
In November, among the 17 analysts covering Baxter International (BAX), ten analysts recommended a “buy” or a higher rating, five recommended a “hold” rating, and three recommended a “sell” rating. The mean rating for Baxter International stock is 2.29 with a target price of $73.27, which implies an upside potential of 11.3% over Baxter International’s closing price of $65.83 on November 15.
Yacktman Asset Management (Trades, Portfolio) Co. sold shares in the following stocks during the third quarter. Warning! GuruFocus has detected 6 Warning Signs with ORCL. The guru trimmed its Oracle Corp. (ORCL) position by 5.77%.
Chairman, CEO of Johnson & Johnson (NYSE:JNJ) Alex Gorsky sold 264,465 shares of JNJ on 11/16/2018 at an average price of $145.96 a share.
Bausch + Lomb/International is a wholly owned subsidiary of Bausch Health Companies (BHC). Bausch + Lomb/International generated revenues of $1.1 billion in the third quarter of this year compared to $1.2 billion in the third quarter of 2017, reflecting a ~7% YoY decline. However, Bausch + Lomb/International witnessed ~3% organic revenue growth.
Baxter International’s (BAX) cost of sales decreased from $1.58 billion in the third quarter of 2017 to $1.53 billion in the third quarter. The company’s gross profit increased from $1.13 billion in the third quarter of 2017 to $1.24 billion in the third quarter due to the favorable product mix and manufacturing efficiencies.
Fluctuations in Baxter International’s (BAX) stock price have kept investors interested in the stock in 2018. In this series, we’ll discuss Baxter International’s financials, analysts’ views on the stock, valuation metrics, and geographic performance. The company’s business units include renal care, medication delivery, pharmaceuticals, clinical nutrition, advanced surgery, and acute therapies.
The case of Bertila Boyd-Bostic, who died of a rare form of cancer in 2017 at the age of 30, is the latest in a series of trials in the United States that centre around allegations that the company's talc-based powder contains cancer-causing asbestos. In May, a deadlocked jury at the Darlington County Court of Common Pleas in Charleston failed to reach a verdict in the first trial. J&J, which denies the allegations, to date has lost two trials and won three in the litigation over whether Johnson's Baby Powder causes mesothelioma, a tissue cancer closely linked to asbestos exposure.
First-of-its-kind contact lens corrects vision and adapts to changing light conditions JACKSONVILLE, Fla. , Nov. 16, 2018 /PRNewswire/ -- TIME has selected ACUVUE OASYS with Transitions Light Intelligent ...
The case of Bertila Boyd-Bostic, who died of a rare form of cancer in 2017 at the age of 30, is the latest in a series of trials in the United States that center around allegations that the company's talc-based powder contains cancer-causing asbestos. In May, a deadlocked jury at the Darlington County Court of Common Pleas in Charleston failed to reach a verdict in the first trial. J&J, which denies the allegations, to date has lost two trials and won three in the litigation over whether Johnson's Baby Powder causes mesothelioma, a tissue cancer closely linked to asbestos exposure.